尼日尔疫情中NmCV-5疫苗对脑膜炎球菌性脑膜炎的有效性:病例对照研究
在尼日尔六个卫生区开展匹配病例对照研究,纳入17例PCR确诊的1-19岁脑膜炎球菌性脑膜炎病例和68名匹配社区对照,评估2024年应急接种中使用的五价结合疫苗NmCV-5的有效性。调整家庭拥挤和近期呼吸道感染史后,总体疫苗有效性为92%(95%CI:72-98),针对NmC为91%(95%CI:63-98),显示在真实疫情条件下高效。
要点
- NmCV-5对总体脑膜炎球菌性脑膜炎的调整VE为92%(95%CI:72-98)。
- 针对NmC的调整VE为91%(95%CI:63-98), crude VE为86%(95%CI:50-96)。
- 研究样本量小,且部分接种状态依赖自我报告,需谨慎解读。
核心结论
- NmCV-5在尼日尔2024年疫情应急接种中对循环的NmC和NmW菌株表现出高有效性。
研究设计与样本
- 匹配病例对照研究,在尼日尔六个卫生区(Niamey IV和Magaria)开展,纳入17例PCR确诊的1-19岁脑膜炎球菌性脑膜炎病例和68名按年龄、性别、居住地匹配的社区对照。
主要发现
- 17例病例中14例为NmC、3例为NmW;7例病例(41%)和58名对照(86%)报告接种NmCV-5。
- 粗VE对全部脑膜炎球菌性脑膜炎为88%(95%CI:62-96),对NmC为86%(95%CI:50-96)。
- 调整家庭拥挤和近期呼吸道感染史后,总体VE为92%(95%CI:72-98),对NmC为91%(95%CI:63-98),敏感性分析证实稳健。
临床怎么用
- 在疫情应对中,NmCV-5可用于目标人群的应急接种以预防NmC和NmW脑膜炎。
- 接种状态应优先以接种卡核实,自我报告可能影响效果评估的准确性。
局限性
- 样本量小。
- 依赖自我报告的接种状态。
- 缺乏其他血清群病例。
- 需进一步研究长期对携带和侵袭性疾病的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningococcal meningitis remains a major public health challenge in Africa's meningitis belt despite the successful elimination of serogroup A epidemics following MenAfriVac introduction. Outbreaks caused by serogroups C, W, and X persist. NmCV-5, a pentavalent conjugate vaccine targeting serogroups A, C, W, Y, and X, was prequalified by WHO in 2023 and used in Niger during reactive vaccination campaigns in 2024. METHODS: We conducted a matched case-control study in six health districts in Niger (Niamey IV and Magaria) to estimate NmCV-5 effectiveness against meningococcal meningitis. Cases were individuals with PCR-confirmed meningococcal meningitis, aged 1-19 years, resident in the vaccination campaign area, and presenting with symptom onset ≥10 days post-campaign. Enrollment took place between May 2024 and July 2025. Four age-, sex-, and residence-matched community controls were enrolled per case. Vaccination status was verified by patient-retained vaccination card when available or self-reported. Logistic regression was used to calculate crude and adjusted vaccine effectiveness (VE). RESULTS: 17 confirmed cases (14 NmC, 3 NmW) and 68 matched community controls were enrolled in the study. Seven cases (41%) and 58 controls (86%) reported NmCV-5 vaccination; vaccination status of all cases and 8 of 58 (14%) controls was confirmed by vaccination card. Crude VE against all meningococcal meningitis was 88% (95% CI: 62-96), and against NmC specifically was 86% (95% CI: 50-96). Adjusted for household crowding and history of recent respiratory infections, VE was 92% (95% CI: 72-98) overall and 91% (95% CI: 63-98) for NmC. Sensitivity analyses confirmed robustness of estimates under extreme assumptions. CONCLUSIONS: NmCV-5 demonstrated high effectiveness against circulating meningococcal strains NmC and NmW in real-world outbreak conditions. Limitations include small sample size, reliance on self-reported vaccination status, and absence of cases from other serogroups. Further studies should assess long-term impact on carriage and effectiveness against invasive disease across all targeted serogroups.
引用
- Cooper LV, Djedanem M, Nasser AA, et al. Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study. Vaccine. 2026. PMID: 42585809. doi:10.1016/j.vaccine.2026.128997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。